<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01311570</url>
  </required_header>
  <id_info>
    <org_study_id>B080910</org_study_id>
    <nct_id>NCT01311570</nct_id>
  </id_info>
  <brief_title>Study Assessing the Safety and Therapeutic Effect of Buprenorphine in MDD Patients</brief_title>
  <official_title>A Single Center, Open Label, Dose-titration, add-on Study Assessing the Feasibility, Safety and Therapeutic Effect of Buprenorphine in Adult Patients With Diagnosis of Major Depression.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shalvata Mental Health Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shalvata Mental Health Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to assess the therapeutic effect of Buprenorphine in&#xD;
      MDD population.&#xD;
&#xD;
      The secondary objectives of this study are to assess the therapeutic effect, the feasibility&#xD;
      and safety of buprenorphine in a MDD population.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>October 2012</start_date>
  <primary_completion_date type="Anticipated">February 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary objective of this study is to assess the therapeutic effect of Buprenorphine in MDD population.</measure>
    <time_frame>from baseline to day 42 [end of Buprenorphine treatment]</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The secondary objectives of this study are to assess the therapeutic effect, the feasibility and safety of buprenorphine in a MDD population.</measure>
    <time_frame>from baseline to day 42 [end of Buprenorphine treatment]</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Depression</condition>
  <arm_group>
    <arm_group_label>Buprenorphine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Buprenorphine</intervention_name>
    <description>In the first 2 weeks all subjects will enter into a dose titration phase, starting with minimum dosage of 1mg/day Buprenorphine gradually increasing to 4-8 mg/day according to tolerance and clinical benefit.&#xD;
From week 3 to week 8, all subjects are prescribed Buprenorphine sublingually, OID in a stable dosage according to the decision of the treating physician.</description>
    <arm_group_label>Buprenorphine</arm_group_label>
    <other_name>subutex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Outpatients and inpatients&#xD;
&#xD;
          -  Men and women 18-68 years of age.&#xD;
&#xD;
          -  Primary DSM-IV diagnosis of Major Depression, single or recurrent episode confirmed by&#xD;
             the Structured Clinical Interview for the DSM-IV (SCID-IV), with the additional&#xD;
             requirements of a current episode ≥4 weeks and CGI-S ≥4.&#xD;
&#xD;
          -  Total HDRS-21 ≥20 and Item 1 score ≥2 at the screening visit.&#xD;
&#xD;
          -  The patient did not respond to at least one antidepressant medication given for an&#xD;
             accepted dose and duration.&#xD;
&#xD;
          -  If currently taking Benzodiazepines, the patient must be clinically appropriate to&#xD;
             discontinue treatment with those agents, and able to tolerate no benzodiazepines&#xD;
             during the study period.&#xD;
&#xD;
          -  Capable and willing to provide informed consent&#xD;
&#xD;
          -  Able to adhere to the treatment schedule.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Depression secondary to a general medical condition.&#xD;
&#xD;
          -  History of substance abuse or dependence within the past 6 month (except nicotine and&#xD;
             caffeine).&#xD;
&#xD;
          -  All antidepressant medications, must have been in stable dosage for at least 6 weeks&#xD;
             prior to entry into the study, with no anticipation of change over the duration of the&#xD;
             study.&#xD;
&#xD;
          -  Use of any medication(s) listed on the Excluded medication list within the time that&#xD;
             mansion for each medication on the list.&#xD;
&#xD;
          -  Any psychotic disorder (lifetime), including schizoaffective disorder, or major&#xD;
             depression with psychotic features • Bipolar disorder • Eating disorder&#xD;
&#xD;
          -  Presence (within 12 months of baseline) of a personality disorder (such as antisocial,&#xD;
             schizotypal, histrionic, borderline, narcissistic) as assessed by the investigator to&#xD;
             be primary, causing a higher degree of distress or impairment than MDD.&#xD;
&#xD;
          -  Use of a Monoamine Oxidase Inhibitor (MAOI) within 2 weeks of the screening visit&#xD;
&#xD;
          -  Use of a CYP3A4 Inhibitors and CYP3A4 Inducers within 2 weeks of screening visit.&#xD;
&#xD;
          -  Present suicidal risk as assessed by the investigator or significant suicide risk&#xD;
             based on HDRS-21 item 3 score of 3 or 4 or a history of attempted suicide in the last&#xD;
             6 month&#xD;
&#xD;
          -  Known or suspected pregnancy&#xD;
&#xD;
          -  Women who are breast-feeding&#xD;
&#xD;
          -  Women of childbearing potential and not using a medically accepted form of&#xD;
             contraception when engaging in sexual intercourse.&#xD;
&#xD;
          -  Patients with severe respiratory insufficiency or asthma - anticipation require&#xD;
             examination of pulmonologist.&#xD;
&#xD;
          -  Patients with severe hepatic or renal insufficiency.&#xD;
&#xD;
          -  Patients with history of head injury, increased intracranial pressure, hypotension,&#xD;
             prostatic hypertrophy or urethral stenosis- anticipation require examination of&#xD;
             neurologist.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>68 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ziv carmel, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>shalvata medical health center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ziv carmel, M.D</last_name>
    <phone>00-972-9-7478644</phone>
    <email>zivca@clalit.org.il</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shalvata Medical Health Center</name>
      <address>
        <city>Hod-Hasharon</city>
        <country>Israel</country>
      </address>
    </facility>
    <contact>
      <last_name>ziv carmel, M.D.</last_name>
      <phone>00-972-9-7478644</phone>
      <email>zivca@clalit.org.il</email>
    </contact>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <study_first_submitted>January 9, 2011</study_first_submitted>
  <study_first_submitted_qc>March 7, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 9, 2011</study_first_posted>
  <last_update_submitted>September 23, 2012</last_update_submitted>
  <last_update_submitted_qc>September 23, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 25, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Buprenorphine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

